Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
复制标题
DOI：
10.4143/crt.2011.43.4.244
复制
发表时间：
2011-12-01
影响因子：
4.6
通讯作者：
Park, Hee Sook
中科院分区：
文献类型：
--
作者：
Kwon, Ji Yeon;Yun, Jina;Park, Hee Sook
目的胃癌骨髓转移患者预后极差。本研究旨在评估进展期胃癌骨髓转移患者的临床结局。材料与方法我们回顾性分析了1986年9月至2009年2月在顺春香大学医院接受治疗的26例进展期胃癌骨髓转移患者的病历。所有患者均为低分化腺癌，包括17例印戒细胞癌。大多数患者有血小板减少症、贫血和乳酸脱氢酶水平升高。16例患者（61.5%）接受姑息化疗（中位数，4个周期;范围，1至13个周期）。检测到骨髓转移后，患者队列的中位总生存期为37天（95%置信区间为12.5至61.5天）。最佳支持治疗组检测到骨髓受累后的中位总生存期为11天（范围，2 - 34天），姑息化疗组为121天（范围，3 - 383天）（P
PurposeThe prognosis of gastric cancer patients with bone marrow metastases is extremely poor. The current study was conducted to evaluate the clinical outcomes of advanced gastric cancer patients with bone marrow metastases.Materials and MethodsWe retrospectively reviewed the medical records of 26 advanced gastric cancer patients with bone marrow metastases who were treated at Soonchunhyang University Hospital between September 1986 and February 2009.ResultsThe median age was 46 years (range, 24 to 61 years). All patients had poorly differentiated adenocarcinoma, including 17 signet ring cell carcinomas. The majority of the patients had thrombocytopenia, anemia, and elevated lactate dehydrogenase levels. Sixteen patients (61.5%) received palliative chemotherapy (median, 4 cycles; range, 1 to 13 cycles). The median overall survival after detection of bone marrow metastases for the cohort of patients was 37 days (95% confidence interval, 12.5 to 61.5 days). The median overall survival after detection of bone marrow involvement was 11 days in the best supportive care group (range, 2 to 34 days) and 121 days (range, 3 to 383 days) in the palliative chemotherapy group (p